Clinical Trials Logo

Malignant Brain Tumor clinical trials

View clinical trials related to Malignant Brain Tumor.

Filter by:

NCT ID: NCT06099743 Not yet recruiting - Glioma Clinical Trials

ASCENT Intervention for Brain Tumor Patients

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to test a psychosocial intervention called ASCENT (ACT-based Supportive intervention for patients with CENTral nervous system tumors). This intervention was developed to help patients after being diagnosed with a brain tumor. The main question this study aims to answer is whether this intervention is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in 6 coaching sessions and complete short surveys at four different time points. Some participants will be asked to share feedback via interviews.

NCT ID: NCT06098248 Not yet recruiting - Clinical trials for Malignant Brain Tumor

cCeLL - Ex Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine if cCeLL imaging is as accurate as standard biopsy practices for brain tumor surgeries. The main question[s] it aims to answer are: - Is it as accurate as standard biopsy practices? - Can it be performed faster than standard biopsy practices? Participants will consent to having their tumor tissue assessed by both cCeLL and standard biopsy procedures. There are no additional participation requirements beyond the tumor removal surgery.

NCT ID: NCT06092125 Recruiting - Parkinson Disease Clinical Trials

Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

CAMIND
Start date: February 1, 2023
Phase:
Study type: Observational

The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are: - Overcome the bottleneck of early accurate diagnosis and treatment in major brain diseases clinical practice. - Promote the clinical application of domestic PET/MR, enhance international competitiveness. Participants will have a PET/MR scan of the brain.

NCT ID: NCT05976490 Recruiting - Glioma Clinical Trials

NeuroPathways Intervention for Brain Tumor Patients

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.

NCT ID: NCT05669326 Not yet recruiting - Clinical trials for Malignant Brain Tumor

Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery

NODDI-TRACT
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate to what extent the capacity of the NODDI model can allow, in case of Malignant brain tumor patients with vasogenic edema, the elaboration of a reliable cerebral functional mapping in accordance with the data of direct electrical stimulation (DES) which is today the reference tool. the patient's participation in this study implies an additional visit during which an MRI examination without injection of contrast medium will be performed, lasting approximately 40 minutes (including installation and de-installation).

NCT ID: NCT05293197 Recruiting - Malignant Glioma Clinical Trials

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

SONOKID
Start date: February 6, 2023
Phase: Phase 1
Study type: Interventional

Purpose : the aim of this study is to assess the feasibility and safety of ultrasound-induced opening of the blood-brain barrier (BBB) with the SonoCloud-9 implantable ultrasound device in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor treated with carboplatin. Study hypothesis : the blood-brain barrier can be transiently and safely opened with pulsed low intensity ultrasound immediately prior to intravenously delivered chemotherapy. The opening of the BBB with the SonoCloud-9 system will increase the tumor exposure to carboplatin and increase progression-free and overall survival in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor.

NCT ID: NCT05169944 Suspended - Brain Cancer Clinical Trials

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

PNOC025
Start date: April 22, 2022
Phase: Phase 1
Study type: Interventional

Children and adults with recurrent or progressive malignant brain tumors have a dismal prognosis, and outcomes remain very poor. Magrolimab is a first-in-class anticancer therapeutic agent targeting the Cluster of differentiation 47 (CD47)-signal receptor protein-alpha (SIRP-alpha) axis. Binding of magrolimab to human CD47 on target malignant cells blocks the "don't eat me" signal to macrophages and enhances tumor cell phagocytosis. Pre-clinical studies have shown that treatment with magrolimab leads to prolonged survival in models of Atypical Teratoid Rhabdoid Tumors (ATRT), diffuse intrinsic pontine glioma (DIPG), high-grade glioma (adult and pediatric), medulloblastoma, and embryonal tumors formerly called Primitive Neuro-Ectodermal Tumors (PNET). Safety studies in humans have proven that magrolimab has an excellent safety profile. Ongoing studies are currently testing magrolimab in adult myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin lymphoma, colorectal, ovarian, and bladder cancers. Herein we propose to test the safety of magrolimab in children and adults with recurrent or progressive malignant brain tumors.

NCT ID: NCT04351035 Completed - Clinical trials for Pediatric Brain Tumor

National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry

Start date: October 27, 2018
Phase:
Study type: Observational [Patient Registry]

Tumours of central nervous system (CNS) is the most common type of solid tumour in childhood. In China, there is limited epidemiology information. Released data from Chinese CDC did not include types of CNS tumours and geographic contribution. As the Children's Neuro-Oncology Group (CNOG) was established in China in May 2017, it makes studies from multiple centers in children's brain tumors become practical. This retrospective cross-sectional study was aligned on CNOG annual meeting in 2018 and research group was named as CNOG-MC001 (MC, multicenter) collaborative group.

NCT ID: NCT04109209 Completed - Anxiety Clinical Trials

Psychological Intervention For Brain Tumor Caregivers

Start date: October 9, 2019
Phase: N/A
Study type: Interventional

This study is testing a supportive psychosocial intervention for caregivers of people who have malignant brain tumors such as gliomas or other high-grade primary brain tumors. This study was designed because caregivers of patients with malignant brain tumors often experience physical and psychological burdens caring for their loved ones. The purpose of this study is to find out whether a program offering psychological support can help caregivers learn effective coping methods during their loved one's treatment and make the experience of being a caregiver more manageable.

NCT ID: NCT02885324 Terminated - Clinical trials for Glioblastoma Multiforme

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Start date: May 18, 2017
Phase: Phase 2
Study type: Interventional

This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival